Press Releases
Oct 19, 2020
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors
Sep 08, 2020
VelosBio Appoints Paul Bavier as General Counsel
Aug 31, 2020
VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma
Aug 03, 2020
VelosBio Appoints Dr. Enoch Kariuki as Chief Financial Officer
Jul 08, 2020
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology
Now Leaving The VelosBio Site.
Disclaimer: The information you have requested is not provided by VelosBio Inc. (“VelosBio”) but by a third party and should not be construed as representing the views of VelosBio. VelosBio does not guarantee the accuracy or completeness of this information and is not liable for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising therefrom.